ArticleBMC nephrology2025
Pericoronary fat attenuation index on coronary CT angiography and cardiovascular risk in patients with coronary artery disease and chronic kidney disease.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundThe pericoronary fat attenuation index (pFAI), derived from coronary computed tomography angiography (CCTA), is an emerging marker of local inflammation of coronary arteries. Its prognostic significance in patients with coronary artery disease (CAD) and chronic kidney disease (CKD), which share common inflammatory pathways, remains uncertain. This study aimed to assess the associations between the pFAI and cardiovascular and mortality risk in patients with concurrent CAD and CKD.
methodsPatients with both CAD and CKD who underwent CCTA within 1 year of invasive coronary angiography were included from Cardiorenal Improvement-Ⅱ. The pFAI was measured around the proximal 40 mm of the left anterior descending artery (LAD), left circumflex artery (LCX), and right coronary artery (RCA). High pFAI values were determined from the median levels of LAD (-81.0 HU), LCX (-78.8 HU) and RCA (-79.4 HU). The primary outcome was major adverse cardiovascular events (MACEs), including cardiovascular mortality, nonfatal myocardial infarction and stroke, and the secondary outcomes were cardiovascular and all-cause mortality. Multivariate Cox proportional hazards regression analysis was used to investigate the associations between pFAI and MACEs and cardiovascular and all-cause mortality.
resultsA total of 444 patients (mean age 70.7 ± 9.6 years, 32% female) were included, and 90 (20.3%) cases of MACE, 68 (15.3%) cases of cardiovascular mortality, and 125 (28.2%) cases of all-cause mortality occurred, with a median follow-up of 4.57 years. For MACEs in patients with high pFAI levels compared with those with low pFAI levels, the multivariable adjusted HR was 1.65 (95% CI: 1.02-2.66; P = 0.042) for LAD, 2.06 (95% CI: 1.23-3.45; P = 0.006) for LCX, and 1.71 (95% CI: 1.07-2.74; P = 0.025) for RCA. For cardiovascular and all-cause mortality, similar significant associations were observed (all P < 0.05).
conclusionsA high pFAI for each major coronary artery was independently associated with an increased risk of MACEs and cardiovascular and all-cause mortality in patients with CAD and CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.